OncoMatch/Clinical Trials/NCT07299292

Castration With Abiraterone 250 mg Without LHRH Analogs or Blockers in Patients With Prostate Cancer Requiring Hormonal Intensification (Multicenter Phase 2)

Is NCT07299292 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Abiraterone 250 mg with food + prednisone for prostate cancer (diagnosis).

Phase 2RecruitingSMED Clinical ResearchNCT07299292Data as of May 2026

Treatment: Abiraterone 250 mg with food + prednisone — Hypothesis The use of Abiraterone 250 mg with food + prednisone, without LHRH analogs or blockers (ADT), achieves castration-level testosterone at 30 days in ≥80-90% of cases.

Check if I qualify

Extracted eligibility criteria

Cancer type

Prostate Cancer

Performance status

ECOG 0–2(Ambulatory, capable of self-care)

Prior therapy

Cannot have received: androgen deprivation therapy

Lab requirements

Kidney function

adequate renal function

Liver function

adequate hepatic function

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify